These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18607142)

  • 21. Optimizing blood pressure control in the obese patient.
    Pischon T; Sharma AM
    Curr Hypertens Rep; 2002 Oct; 4(5):358-62. PubMed ID: 12217253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of obesity-associated hypertension].
    Scholze J; Patschan S; Dörffel Y; Hansen A
    Dtsch Med Wochenschr; 2005 Nov; 130(46):2645-50. PubMed ID: 16281161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a rationale for angiotensin blockade in the management of obesity hypertension?
    Sharma AM
    Hypertension; 2004 Jul; 44(1):12-9. PubMed ID: 15173127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
    Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
    Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic options for metabolic syndrome in obese patients].
    Carella AM; Conte M
    Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology and treatment of the obesity-related arterial hypertension.
    Kolanowski J
    Acta Clin Belg Suppl; 1992; 14():18-25. PubMed ID: 1604957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements.
    Masuo K
    Curr Hypertens Rev; 2015; 11(1):61-77. PubMed ID: 25882380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sympathetic nervous system and insulin resistance: from obesity to diabetes.
    Esler M; Rumantir M; Wiesner G; Kaye D; Hastings J; Lambert G
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):304S-309S. PubMed ID: 11721888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome.
    Sharma AM; Engeli S
    J Cardiometab Syndr; 2006; 1(1):29-35. PubMed ID: 17675902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of obesity hypertension and diabetes syndrome.
    Zanella MT; Kohlmann O; Ribeiro AB
    Hypertension; 2001 Sep; 38(3 Pt 2):705-8. PubMed ID: 11566961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension.
    Carnagarin R; Gregory C; Azzam O; Hillis GS; Schultz C; Watts GF; Bell D; Matthews V; Schlaich MP
    Curr Hypertens Rep; 2017 Oct; 19(12):99. PubMed ID: 29080925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension.
    Jordan J; Yumuk V; Schlaich M; Nilsson PM; Zahorska-Markiewicz B; Grassi G; Schmieder RE; Engeli S; Finer N
    J Hypertens; 2012 Jun; 30(6):1047-55. PubMed ID: 22573071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology of obesity hypertension.
    Hall JE
    Curr Hypertens Rep; 2000 Apr; 2(2):139-47. PubMed ID: 10981140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.
    Lambert GW; Straznicky NE; Lambert EA; Dixon JB; Schlaich MP
    Pharmacol Ther; 2010 May; 126(2):159-72. PubMed ID: 20171982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal changes of blood pressure after weight loss: factors involved.
    Flores L; Vidal J; Núñez I; Rueda S; Viaplana J; Esmatjes E
    Surg Obes Relat Dis; 2015; 11(1):215-21. PubMed ID: 25304830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.